JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB27278

Anti-VEGF Receptor 3 antibody

4

(8 Reviews)

|

(63 Publications)

Anti-VEGF Receptor 3 antibody (ab27278) is a rabbit polyclonal antibody detecting VEGF Receptor 3 in Western Blot, IHC- Wmt, ICC/IF. Suitable for Human, Mouse, Rat.

- Over 40 publications
- Trusted since 2005

View Alternative Names

VEGFR3, FLT4, Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, Tyrosine-protein kinase receptor FLT4, FLT-4

3 Images
Western blot - Anti-VEGF Receptor 3 antibody (AB27278)
  • WB

Lab

Western blot - Anti-VEGF Receptor 3 antibody (AB27278)

Anti-FLT4 antibody (ab27278) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab27278 was shown to bind specifically to FLT4 but with several non-specific bands. We recommend ab243232 for Western blot. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-VEGF Receptor 3 antibody (ab27278) at 1/1000 dilution

Lane 1:

HEL 92.1.7 cell lysate at 20 µg

Lane 2:

MCF7 cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 146 kDa

Observed band size: 200 kDa

false

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 3 antibody (AB27278)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 3 antibody (AB27278)

ICC/IF image of ab27278 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab27278, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Western blot - Anti-VEGF Receptor 3 antibody (AB27278)
  • WB

Unknown

Western blot - Anti-VEGF Receptor 3 antibody (AB27278)

Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1 : 50 for 2 hours at room tepterature Hey cell lysate (50µg/lane) was used. The antibody was diluted at 1 : 50 for 2 hours at room temperature. The protein is heavily glycosylated and this might explain the increase in MW above the predcted MW as well as the multiple bands.

All lanes:

Western blot - Anti-VEGF Receptor 3 antibody (ab27278) at 1/50 dilution

Predicted band size: 146 kDa

Observed band size: 170 kDa,200 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human, Rat, Mouse

Applications

ICC/IF, WB, IHC - Wmt

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCWmt" : {"fullname" : "IHC - Wholemount", "shortname":"IHC - Wmt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "1/100", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1 µg/mL", "ICCIF-species-notes": "<p></p>", "IHCWmt-species-checked": "guaranteed", "IHCWmt-species-dilution-info": "", "IHCWmt-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCWmt-species-checked": "guaranteed", "IHCWmt-species-dilution-info": "", "IHCWmt-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCWmt-species-checked": "guaranteed", "IHCWmt-species-dilution-info": "", "IHCWmt-species-notes": "<p></p>" } } }

Product details

What is this antibody validated in?
Anti-VEGF Receptor 3 antibody (ab27278) is a rabbit polyclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC - Wmt), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples.

What is the molecular weight of VEGF Receptor 3?
Anti-VEGF Receptor 3 (ab27278) specifically detects a band for VEGF Receptor 3 (UniProt: P35916) at a molecular weight of 146kDa.

Trusted by the scientific community
Anti-VEGF Receptor 3 (ab27278) was first used in a scientific publication in 2005 and has been cited over 40 times in peer-reviewed journals.

Reviewed by scientists
Anti-VEGF Receptor 3 (ab27278) has over 5 independent reviews from customers.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 3 also known as FLT-4 is a protein essential for lymphatic development and is expressed mainly in lymphatic endothelial cells. This receptor has a molecular mass of approximately 195 kDa. VEGF Receptor 3 belongs to the tyrosine kinase family and binds with high affinity to its ligands VEGF-C and VEGF-D. These interactions lead to the activation of intracellular signaling cascades that promote cell proliferation migration and survival.
Biological function summary

The VEGF Receptor 3 acts as an important regulator of lymphangiogenesis which is the growth of new lymphatic vessels from pre-existing ones. It is not typically part of larger protein complexes but it works closely with its ligands to facilitate the processes associated with lymph vessel formation and function. Proper activity of VEGF Receptor 3 is necessary for maintaining normal lymphatic vessel remodeling and function during development and in some adult tissues.

Pathways

The receptor is involved in the VEGF signaling pathway which plays an important role in vascular and lymphatic development. This pathway intersects with others like the PI3K/AKT pathway a critical mediator of cell growth and survival. VEGF Receptor 3 interacts with related receptors such as VEGF Receptor 2 in these pathways to regulate complex and essential physiological processes.

VEGF Receptor 3 has been linked to lymphedema which is swelling due to lymphatic system dysfunction and certain cancers where excessive angiogenesis occurs. Mutations or dysregulations in the receptor's signaling can lead to these conditions. In cancer for instance VEGF Receptor 3 along with its associated protein VEGF-C can promote tumor lymphangiogenesis facilitating metastasis. Antagonists like anti-VEGF therapies target these receptors to inhibit tumor progression and manage these disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.
See full target information FLT4

Publications (63)

Recent publications for all applications. Explore the full list and refine your search

Journal of clinical and translational hepatology 13:555-567 PubMed40937080

2025

CCNE1 Promotes the Progression of Hepatic Precancerous Lesion and the Malignant Phenotype of Hepatocellular Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Kai Zhang,Xue Hu,Lichao Yao,Wenzhi Guo

Journal of tissue engineering 16:20417314251360755 PubMed40792201

2025

Transplantation of engineered vascularized lymphatic tissue using LEC and in vivo AV loop model to enhance lymphangiogenesis and restore lymphatic drainage in a lymphadenectomy rat model.

Applications

Unspecified application

Species

Unspecified reactive species

Gina A Mackert,Hui-Yi Hsiao,Yung-Chun Chang,Robin T Wu,Rushil R Dang,Richard Tee,Jung-Ju Huang

Science progress 107:368504241274022 PubMed39196593

2024

Clinical course and vascular endothelial growth factor signaling system expression in maxillary angiosarcoma: A case report.

Applications

Unspecified application

Species

Unspecified reactive species

Shiho Arai,Takeshi Igarashi,Hiroki Goto,Kazutaka Kashima,Toru Sasaki,Mio Sakaguchi,Noriyoshi Fukushima,Hiroyuki Fujii,Hiroshi Nishino,Makoto Ito,Takeharu Kanazawa

Cell biology international 48:1680-1697 PubMed39099163

2024

CD34 stromal cells/telocytes and their role in mouse lung development: Light microscopy, immunofluorescence, ultrastructural and scanning electron microscopy evidence.

Applications

Unspecified application

Species

Unspecified reactive species

Ganesh Dama,Chengxu Xue,Yangxia Zhang,Dezhuang Li,Jinyu Fan,Liang Qiao,Zhihao Xu,Ciqing Yang,Yanli Liu,Mohammad Farris Iman Leong Bin Abdullah,Juntang Lin

Theranostics 14:1909-1938 PubMed38505607

2024

Neutrophil extracellular trap-mediated impairment of meningeal lymphatic drainage exacerbates secondary hydrocephalus after intraventricular hemorrhage.

Applications

Unspecified application

Species

Unspecified reactive species

Qiang Zhang,Yujie Chen,Yingpei Li,Zhou Feng,Liang Liang,Xiaoke Hao,Wenbo Kang,Zhaoqi Zhang,Xuyang Zhang,Rong Hu,Hua Feng,Zhi Chen

Anais brasileiros de dermatologia 99:362-369 PubMed38350760

2024

Clinicopathological and immunohistochemical characteristics of bullous pilomatricoma: a retrospective, single-center study, and comparison with ordinary pilomatricoma.

Applications

Unspecified application

Species

Unspecified reactive species

Kyung-Hwa Nam,Sang-Kyung Lee,Il-Jae Lee,Jin Park,Seok-Kweon Yun

Scientific reports 13:16844 PubMed37803074

2023

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Anja Charlotte Lundgren Mortensen,Hanna Berglund,Mehran Hariri,Eleftherios Papalanis,Christer Malmberg,Diana Spiegelberg

Frontiers in cell and developmental biology 11:1228344 PubMed37795263

2023

Widespread distribution of lymphatic vessels in human dura mater remote from sinus veins.

Applications

Unspecified application

Species

Unspecified reactive species

César Luis Vera Quesada,Shreyas Balachandra Rao,Reidun Torp,Per Kristian Eide

Cancer gene therapy 30:1260-1273 PubMed37286729

2023

ANRIL promotes the regulation of colorectal cancer on lymphatic endothelial cells via VEGF-C and is the key target for Pien Tze Huang to inhibit cancer metastasis.

Applications

Unspecified application

Species

Unspecified reactive species

Bin Huang,Yao Lu,Zhuona Ni,Jinhong Liu,Yanbin He,Honglin An,Feimin Ye,Jiayu Shen,Minghe Lin,Yong Chen,Jiumao Lin

International journal of molecular sciences 24: PubMed36835014

2023

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Sandra Torres-Ruiz,Eduardo Tormo,Iris Garrido-Cano,Ana Lameirinhas,Federico Rojo,Juan Madoz-Gúrpide,Octavio Burgués,Cristina Hernando,Begoña Bermejo,María Teresa Martínez,Ana Lluch,Juan Miguel Cejalvo,Pilar Eroles
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com